GlassScriptPhysician profile
Shams Iqbal
NPI 1598846834
$3,293.48
in general payments reported to CMS, 2019-2025
25 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.39 · 2020: $62.17 · 2021: $36.91 · 2022: $188 · 2023: $620 · 2024: $931 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,942.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $574.05 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $515.42 | 2022-2025 | Haegarda, Andembry, Hizentra |
| Biocryst US Sales Co., LLC | $274.74 | 2022-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $269.70 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $255.26 | 2024-2025 | Fasenra, Breztri, Airsupra |
| Genentech USA, INC. | $183.77 | 2021-2025 | Xolair |
| Octapharma USA, INC. | $158.81 | 2019-2024 | Cutaquig, Octagam Immune Globulin (Human), Panzyga |
| Takeda Pharmaceuticals U.S.A., INC. | $151.87 | 2023-2025 | Takhzyro |
| Ionis Pharmaceuticals, INC. | $146.22 | 2025 | Dawnzera |
| Regeneron Healthcare Solutions, INC. | $140.31 | 2023-2025 | Dupixent |
| Pfizer INC. | $120.27 | 2024-2025 | |
| Genzyme Corporation | $112.63 | 2022-2025 | |
| Pharming Healthcare, INC. | $60.95 | 2025 | Ruconest |
| Grifols USA, LLC | $58.40 | 2022-2024 | Xembify |
| Kaleo, INC. | $39.70 | 2023-2024 | Auvi-Q |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $29.94 | 2024 | Vyjuvek |
| Blueprint Medicines Corporation | $27.62 | 2023 | Ayvakit |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $26.28 | 2025 | Neffy |
| Cycle Pharmaceuticals INC | $23.88 | 2025 | Sajazir |
| Nestle Healthcare Nutrition INC. | $22.83 | 2023 | |
| Horizon Therapeutics Plc | $21.18 | 2019 | |
| Phadia US INC. | $19.22 | 2023 | Immunocap |
| Insmed, INC. | $18.56 | 2025 | Brinsupri |
| Optinose US, INC. | $14.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shams Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.